Aptose Biosciences

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in Canaccord Genuity's 2021 Horizons in Oncology Virtual Conference:

Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

Aptose offered a clinical update with its fourth quarter earnings report that included no new safety/toxicity concerns for luxeptinib, suggesting prior signals were one-offs unrelated to the drug. A complete response in the AML study, at what should be a borderline therapeutic dose level, is encouraging, as is anecdotal reports of other patients seeing blast reductions.

Aptose Provides An Encouraging Update, But The Road Ahead Is Still Long

The stock price of Aptose Biosciences Inc (NASDAQ: APTO) has increased by 66.21% today. This is why it happened.

APTO Stock Price Increased 66.21%: Why It Happened

Aptose Biosciences Inc. (NASDAQ: APTO) shares traded higher after the company's release of fourth-quarter results Tuesday.  The stock gained 66.21% in Wednesday's regular session, closing at $6.10.

Aptose Biosciences Stock Trades Higher After Q4 Earnings: Technical Levels To Watch

The company reported very encouraging results from an early-stage study.

Why Aptose Biosciences Stock Is Skyrocketing Today

APTO stock is rocketing this morning as the company releases some encouraging research details alongside its Q4 earnings report. The post APTO Stock: Why Aptose Biosciences Is Rocketing Higher Today appeared first on InvestorPlace.

APTO Stock: Why Aptose Biosciences Is Rocketing Higher Today

The stock price of Aptose Biosciences Inc (NASDAQ: APTO) has increased by over 25% pre-market. This is why it happened.

APTO Stock Price Increases Over 25% Pre-Market: Why It Happened

Aptose Biosciences Inc. (APTO) CEO William Rice on Q4 2020 Results - Earnings Call Transcript

- Conference call and webcast at 5pm EDT today -

Aptose Reports Results for the Fourth Quarter and Full Year 2020

SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter ended December 31, 2020, on Tuesday, March 23, 2021 after the close of the market.

Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021

Aptose Biosciences (APTO) has been struggling lately, but the selling pressure may be coming to an end soon.

Aptose Biosciences (APTO) Sees Hammer Chart Pattern: Time to Buy?

Aptose shares are weak in post-ASH trading as the Phase I CG-806 study has yet to produce a clinical response in B-cell malignancies. Three B-cell patients did see some tumor reduction at lower doses of CG-806, and the expansion to 750mg (and possibly higher doses) could finally drive meaningful responses.

Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents

SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December 6th, in conjunction with participation at the 2020 American Society of Hematology (ASH) Annual Meeting. The Aptose management team reviewed the current clinical status of CG-806, Aptose's oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor currently in two Phase 1 a/b trials, one trial in patients with relapsed or refractory acute myeloid leukemia (AML), and the other trial in patients with relapsed or refractory B cell malignancies; and the team also reviewed the clinical status of APTO-253, a first-in-class small molecule MYC inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

Aptose Presents Highlights from ASH and Corporate Update Event

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

Implied Volatility Surging for Aptose (APTO) Stock Options

Aptose (APTO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Strength Seen in Aptose (APTO): Stock Soars 5.3%

Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers

Aptose to Hold Corporate Update Sunday, December 6th

Aptose shares have been weak of late, but there have been no negative updates to the company's core clinical programs, and management recently started its third trial (CG-806 in AML). It is unclear whether the upcoming ASH meeting will provide meaningful efficacy information on CG-806; management has reported seeing "nodal reductions," but no formal responses yet.

Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data

Aptose Biosciences' (APTO) CEO William Rice on Q3 2020 Results - Earnings Call Transcript

Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level

Aptose Reports Results for the Third Quarter 2020

Abstracts Accepted for Presentation Abstracts Accepted for Presentation

Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting

SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2020 on Tuesday, November 10, 2020, after the close of the market.

Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020

Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.

Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients

Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg

Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia

SAN DIEGO and TORONTO, Sept.  15, 2020  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit:

Aptose to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Aptose Biosciences (APTO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

News for Aptose Biosciences Stock (APTO)